These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23881311)

  • 1. A novel 'pipeline' system for downstream preparation of therapeutic monoclonal antibodies.
    Wang F; Yan X; Song L; Wang P; Lu D; Feng J; Yang D; Yan X
    Biotechnol Lett; 2013 Sep; 35(9):1411-8. PubMed ID: 23881311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host cell proteins in biotechnology-derived products: A risk assessment framework.
    de Zafra CL; Quarmby V; Francissen K; Vanderlaan M; Zhu-Shimoni J
    Biotechnol Bioeng; 2015 Nov; 112(11):2284-91. PubMed ID: 26010760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aggregates in monoclonal antibody manufacturing processes.
    Vázquez-Rey M; Lang DA
    Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clarification technologies for monoclonal antibody manufacturing processes: Current state and future perspectives.
    Singh N; Arunkumar A; Chollangi S; Tan ZG; Borys M; Li ZJ
    Biotechnol Bioeng; 2016 Apr; 113(4):698-716. PubMed ID: 26302443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of difficult-to-remove host cell protein impurities during extended Chinese hamster ovary cell culture and their impact on continuous bioprocessing.
    Valente KN; Lenhoff AM; Lee KH
    Biotechnol Bioeng; 2015 Jun; 112(6):1232-42. PubMed ID: 25502542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational and systematic protein purification process development: the next generation.
    Nfor BK; Verhaert PD; van der Wielen LA; Hubbuch J; Ottens M
    Trends Biotechnol; 2009 Dec; 27(12):673-9. PubMed ID: 19815300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a multi-product leached protein A assay for bioprocess samples containing recombinant human monoclonal antibodies.
    Ren D; Darlucio MR; Chou JH
    J Immunol Methods; 2011 Mar; 366(1-2):20-7. PubMed ID: 21315722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous downstream processing of biopharmaceuticals.
    Jungbauer A
    Trends Biotechnol; 2013 Aug; 31(8):479-92. PubMed ID: 23849674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility study of semi-selective protein precipitation with salt-tolerant copolymers for industrial purification of therapeutic antibodies.
    Capito F; Bauer J; Rapp A; Schröter C; Kolmar H; Stanislawski B
    Biotechnol Bioeng; 2013 Nov; 110(11):2915-27. PubMed ID: 23637026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of endotoxin contamination during production of a therapeutic serum.
    Massaldi H; Morais V
    PDA J Pharm Sci Technol; 2007; 61(5):375-82. PubMed ID: 18047176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of protein engineering and process optimization approaches to enhance antibody drug manufacturability.
    Conley GP; Viswanathan M; Hou Y; Rank DL; Lindberg AP; Cramer SM; Ladner RC; Nixon AE; Chen J
    Biotechnol Bioeng; 2011 Nov; 108(11):2634-44. PubMed ID: 21618474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viruses and assuring viral safety.
    Robertson JS
    Dev Biol (Basel); 2003; 113():73-7. PubMed ID: 14620855
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety risk management for low molecular weight process-related impurities in monoclonal antibody therapeutics: Categorization, risk assessment, testing strategy, and process development with leveraging clearance potential.
    Luo H; Li Y; Robbins D; Wang SC; Xi G; Cox M; Nicholson SM; Wei C; Pabst TM; Wang WK
    Biotechnol Prog; 2021 May; 37(3):e3119. PubMed ID: 33373106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development.
    den Engelsman J; Garidel P; Smulders R; Koll H; Smith B; Bassarab S; Seidl A; Hainzl O; Jiskoot W
    Pharm Res; 2011 Apr; 28(4):920-33. PubMed ID: 20972611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. State-of-the-art in downstream processing of monoclonal antibodies: process trends in design and validation.
    Marichal-Gallardo PA; Alvarez MM
    Biotechnol Prog; 2012 Jul; 28(4):899-916. PubMed ID: 22641473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine contamination of biological products.
    Wadhwa M; Thorpe R
    Biologicals; 1997 Sep; 25(3):307-18. PubMed ID: 9324999
    [No Abstract]   [Full Text] [Related]  

  • 17. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
    Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
    Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using partition designs to enhance purification process understanding.
    Pieracci J; Perry L; Conley L
    Biotechnol Bioeng; 2010 Dec; 107(5):814-24. PubMed ID: 20632374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contamination Control.
    Akers MJ
    Int J Pharm Compd; 2015; 19(3):232-8. PubMed ID: 26714364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Process scale considerations in evaluation studies and scale-up.
    Walter JK; Werz W; Berthold W
    Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.